Genetic Polymorphisms of Matrix Metalloproteinases and Clinical Outcomes in Colorectal Cancer Patients

Wen-Chien Ting¹²³*, Lu-Min Chen⁴, Jiunn-Bey Pao⁵*, Ying-Pi Yang⁵, Bang-Jau You⁶, Ta-Yuan Chang⁷, Yu-Hsuan Lan⁸, Hong-Zin Lee⁸, Bo-Ying Bao⁸⁹, *

¹. Department of Colorectal Surgery, China Medical University Hospital, Taichung, Taiwan
². Division of Colorectal Surgery, Department of Surgery, Chung Shan Medical University Hospital, Taichung, Taiwan
³. Institute of Medicine, Chung Shan Medical University, Taichung, Taiwan
⁴. Department of Obstetrics and Gynecology, China Medical University Hospital, Taichung, Taiwan
⁵. Department of Pharmacy, Yangming Branch, Taipei City Hospital, Taipei, Taiwan
⁶. Department of Chinese Medicine Resources, China Medical University, Taichung, Taiwan
⁷. Department of Occupational Safety and Health, China Medical University, Taichung, Taiwan
⁸. Department of Pharmacy, China Medical University, Taichung, Taiwan
⁹. Sex Hormone Research Center, China Medical University Hospital, Taichung, Taiwan

*Wen-Chien Ting, Lu-Min Chen, and Jiunn-Bey Pao contributed equally to this work.

Corresponding author: Bo-Ying Bao, Department of Pharmacy, China Medical University, 91 Hsueh-Shih Road, Taichung 40402, Taiwan.
Phone: 886-4-22053366 ext. 5126; Fax: 886-4-22031075; E-mail: bao@mail.cmu.edu.tw.

© Ivyspring International Publisher. This is an open-access article distributed under the terms of the Creative Commons License (http://creativecommons.org/licenses/by-nc-nd/3.0/). Reproduction is permitted for personal, noncommercial use, provided that the article is in whole, unmodified, and properly cited.

Received: 2013.05.14; Accepted: 2013.06.05; Published: 2013.06.15

Abstract

Background: Colorectal cancer metastasis is a multistep process involving degradation of extracellular matrix components by proteolytic enzymes. Among them, matrix metalloproteinases (MMPs) are the principal degrading enzymes and their expressions/activities are also correlated with survival. Much research has showed the associations between genetic polymorphisms in MMPs and risk of colorectal cancer; however, their prognostic significance has not been well determined.

Methods: We selected and genotyped 4 cancer-associated single nucleotide polymorphisms (SNPs) in a cohort of 282 colorectal cancer patients. The associations of these SNPs with distant metastasis-free survival and overall survival were evaluated by Kaplan-Meier analysis, Cox regression model, and survival tree analysis.

Results: The relative risks of developing distant metastasis after curative surgery were higher in individuals with minor homozygote AA genotype than in those with GG/GA genotypes at MMP2 rs243866 (P = 0.012). Survival tree analysis also identified a higher-order genetic interaction profile consisting of MMP2 rs243866 and MMP2 rs2285053 that was significantly associated with distant metastasis-free survival (P_trend = 0.016). After adjusting for possible confounders, the genetic interaction profile remained significant (P_trend = 0.050).

Conclusions: These results suggest that genetic variations in the MMP2 might be potential predictors of distant metastasis-free survival after curative surgery.

Key words: colorectal cancer, matrix metalloproteinases, single nucleotide polymorphism, metastasis, survival.

Introduction

Colorectal cancer remains one of the leading causes of cancer death worldwide and in Taiwan. The 5-year survival rates are approximately 90% for early stage colorectal cancer patients, but decreasing to less...
than 10% in patients with distant metastases [1]. In addition, about 25 to 40 percent of patients who undergo curative surgery for localized colorectal cancer eventually recur and develop metastases, but current clinicopathologic indicators do not predict the outcomes [2]. Therefore, there is a need to identify and select appropriate adjuvant therapy for patients at high risk in development of metastases.

Cancer metastasis is a complex multifactorial and multistep process, involving invasion of stroma, intravasation into the circulation from the primary site, extravasation at the secondary site, and outgrowth of new tumors. These processes require degradation of the extracellular matrix components by proteolytic enzymes. The most important proteinases capable of creating a pathway for tumor cell migration are the matrix metalloproteinases (MMPs). One particular group of MMPs, the gelatinases A and B also known as MMP2 and MMP9, play a crucial role during colorectal cancer invasion and metastasis. The levels of gene expression and enzymatic activity of MMP2 and MMP9 were higher in tumors compared with normal mucosa, and their overexpression is associated with a poor prognosis in colorectal cancer patients [3-5].

Lots of molecular epidemiological studies have focused on the associations between MMP polymorphisms and the risk of colorectal cancer [6-10], but little is known about their relationship to cancer prognosis. Thus, the aim of the present study was to assess the association of MMP2 and MMP9 single-nucleotide polymorphisms (SNPs) with distant metastasis-free and overall survival in a cohort of 282 colorectal cancer patients.

**Materials and Methods**

**Patient recruitment and data collection**

Two hundred and eighty-two colorectal cancer patients were retrospectively examined the records in the China Medical University Hospital, Taiwan between 2001 and 2007. All cases were histopathologically confirmed, and the clinical data and outcomes were obtained from patients’ clinical records and pathological reports. Among patients receiving curative surgery (stage I-III, n = 233), distant metastasis-free survival was defined as the time from surgery to the date of distant metastases or when censored at the latest date. Overall survival was defined as the time from diagnosis (n = 282) to the date of death from any cause or when censored at the latest date if patients were still alive. The survival data were updated most recently in 2010. This study was approved by the Institutional Review Board of the China Medical University Hospital and written informed consent was obtained from all patients.

**SNP selection and genotyping**

Four SNPs in MMP2 and MMP9 were selected based on the evidence of association with cancers [11-13]. The MMP2 rs243866 (-1575) located immediately 5’ to the potential estrogen receptor binding site and functioned as an enhancer [14]. The MMP2 rs2285053 (-735) have been shown to affect MMP2 expression by lowering transcriptional activity [15, 16]. Several studies have evaluated the association of MMP9 rs3787268 and rs17577 with cancer susceptibility, such as breast [12], prostate [13], and colorectal [17] cancers, but their clinical impact on cancer prognosis and outcomes has not been well evaluated. The MMP9 rs17577 (rs2274756, Arg668Gln) is in the hemopexin-like domain and probably functions in substrate binding, since removal of this domain disables the cleavage of collagen [18].

Genomic DNA was extracted from peripheral blood using the QIAamp DNA Blood Mini Kit (Qiagen, Valencia, CA, USA) and stored at -80°C until the time of study. Genotyping was performed as described previously [19-24] using Sequenom iPLEX matrix-assisted laser desorption/ionization-time of flight mass spectrometry technology at the National Center for Genome Medicine, Academia Sinica, Taiwan. The SNPs were all in Hardy-Weinberg equilibrium (P > 0.05), and the average genotype call rate for these SNPs was 99.5%.

**Statistical analysis**

Patient clinicopathologic characteristics were summarized as number and percentage of patients or median and interquartile range (IQR) of values. Age was dichotomized at the median value within the cohort. Carcinoembryonic antigen (CEA) level was dichotomized at 5 μg/L because of its correlation with an increasing stage of the colorectal cancer [25]. The associations of 4 MMP SNPs and clinical characteristics with distant metastasis-free and overall survival were assessed using Cox proportional hazards model and Kaplan-Meier analysis with log-rank test. We tested different genetic models, dominant, recessive, and additive models for each SNP. The model with the most significant P value was considered the best-fitting model. Higher order SNP-SNP interactions were evaluated using survival tree analysis by STREE software (http://c2s2.yale.edu/software/STREE/), which uses recursive partitioning to identify subgroups of individuals with similar risk [26]. Patients were then categorized into low-, medium-, and high-risk groups based on the survival tree analysis. Multivariate analyses to determine the interdependency of genotypes and other known prognostic fac-
tors, such as age at diagnosis, gender, CEA levels, tumor differentiation, stage, lymphovascular invasion, perineural invasion, and lymph node involvement, were carried out using Cox proportional hazards model. Statistical Package for the Social Sciences software version 19.0.0 (IBM, Armonk, NY) was used for other statistical analyses. A two-sided $P$ value of $\leq 0.05$ was considered statistically significant.

**Results**

DNA was extracted for analysis from the blood samples of 282 colorectal cancer patients. Of the 233 patients receiving curative surgery (stage I-III), 30 (12.9%) developed distant metastasis during the median follow-up of 54.5 months (Table 1). Among the 282 patients diagnosed with colorectal cancer, 92 (32.6%) died after a median follow-up of 50.0 months. Stage, lymphovascular invasion, and lymph node involvement were significantly associated with both distant metastasis-free and overall survival. Gender, CEA levels, tumor differentiation, and perineural invasion were only associated with overall survival, and age was only associated with distant metastasis-free survival.

We assessed the association of 4 MMP SNPs with distant metastasis-free and overall survival under dominant, recessive, and additive genetic models (Table 2). We defined the model with the most significant $P$ value as the best model. Patients carrying AA genotype, minor allele homozygote, of MMP2 rs243866 had a significantly increased risk of developing distant metastasis following curative surgery compared with those with at least one G, major allele [hazard ratio (HR): 6.32, 95% confidence interval (CI): 1.50-26.7, $P = 0.012$]. We did not observe statistically significant relations between other MMP SNPs and distant metastasis-free and overall survival. We also found no association between the 4 MMP SNPs with clinicopathologic features listed in Table 1, except for the MMP2 rs2285053 showing a significant association with CEA levels ($P = 0.030$, data not shown).

We noted that the association of MMP2 rs243866 with distant metastasis-free survival was based on a very low number of minor allele homozygous patients ($n = 4$) and required more cautious interpretation. Thus, we further used survival tree analysis to explored higher order SNP-SNP interactions to evaluate whether the interactions among MMP SNPs could determine the clinical outcomes. The tree structure resulted in 3 terminal nodes, ranging from low, medium, and high risk in developing distant metastasis after curative surgery (Fig. 1A). When using low risk node 4 as the reference group (wild-type homozygous genotypes of MMP2 rs2285053 and MMP2 rs243866), the HR was 2.79 (95% CI, 1.04-7.53, Table 3) for medium risk node 1, and 3.70 (95% CI, 1.18-11.7) for high risk node 3 ($P_{trend} = 0.017$). The time to develop distant metastasis decreased as the increase in risk classification by MMP2 SNPs (log-rank $P = 0.016$, Fig. 1B). However, no genetic interaction was observed for overall survival.

To adjust for potential confounding between the genetic interactions of MMP2 SNPs and distant metastasis-free survival, a Cox proportional hazards model was constructed. The multivariable model was adjusted for age, gender, CEA levels, tumor differentiation, stage, lymphovascular invasion, perineural invasion, and lymph node involvement as covariates. The genetic interaction profile between MMP2 rs2285053 and MMP2 rs243866 remained significantly associated with distant metastasis-free survival (HR: 1.77, 95% CI: 1.00-3.15, adjusted $P_{trend} = 0.050$, Table 3).

![Figure 1. Potential higher order SNP-SNP interactions between MMP2 gene polymorphisms. (A) Survival tree analysis identifies the interactions between MMP2 gene polymorphisms. (B) Kaplan-Meier curves of distant metastasis-free survival based on the survival tree analysis. Numbers in parentheses indicate the number of patients.](http://www.medsci.org)
Table 1. Demographic and clinical characteristics of colorectal cancer patients.

| Characteristics | Distant metastasis-free survival | Overall survival |
|-----------------|---------------------------------|------------------|
|                 | n (%)*                         | of events*       | HR (95% CI) | P | n (%)*     | of events* | HR (95% CI) | P |
| All patients    | 233                            | 30               |              |   | 282        | 92        |              |   |
| Age, years      |                                |                  |              |   |            |           |              |   |
| Median (IQR)    |                                |                  |              |   |            |           |              |   |
| <65             | 106 (45.5)                     | 19               | 1.00         |   | 133 (47.2) | 42        | 1.00         |   |
| ≥65             | 127 (54.5)                     | 11               | 0.48 (0.23-1.00) | 0.049 | 149 (52.8) | 50        | 1.09 (0.72-1.64) | 0.692 |
| Gender          |                                |                  |              |   |            |           |              |   |
| Male            | 119 (51.1)                     | 17               | 1.00         |   | 148 (52.5) | 57        | 1.00         |   |
| Female          | 114 (48.9)                     | 13               | 0.78 (0.38-1.61) | 0.508 | 134 (47.5) | 35        | 0.65 (0.43-0.99) | 0.045 |
| CEA, μg/L       |                                |                  |              |   |            |           |              |   |
| Median (IQR)    |                                |                  |              |   |            |           |              |   |
| <5              | 129 (59.7)                     | 14               | 1.00         |   | 136 (52.3) | 23        | 1.00         |   |
| ≥5              | 87 (40.3)                      | 15               | 1.61 (0.78-3.34) | 0.198 | 124 (47.7) | 58        | 3.35 (2.07-5.44) | <0.001 |
| Differentiation |                                |                  |              |   |            |           |              |   |
| Well            | 43 (20.0)                      | 5                | 1.00         |   | 51 (19.4)  | 11        | 1.00         |   |
| Moderate        | 153 (70.8)                     | 17               | 0.95 (0.35-2.56) | 0.912 | 185 (70.3) | 62        | 1.64 (0.86-3.12) | 0.131 |
| Poor            | 19 (9.2)                       | 6                | 3.17 (0.97-10.4) | 0.057 | 27 (10.3)  | 15        | 3.59 (1.65-7.83) | 0.001 |
| Stage†          |                                |                  |              |   |            |           |              |   |
| I-II            | 150 (64.7)                     | 12               | 1.00         |   |            |           |              |   |
| III             | 82 (35.3)                      | 18               | 2.92 (1.41-6.06) | 0.004 |            |           |              |   |
| I-III           |                                |                  |              |   |            |           |              |   |
| IV              |                                |                  |              |   |            |           |              |   |
| Lymphovascular invasion |                  |                  |              |   |            |           |              |   |
| Negative        | 179 (76.8)                     | 14               | 1.00         |   | 201 (71.3) | 48        | 1.00         |   |
| Positive        | 54 (23.2)                      | 16               | 4.13 (2.02-8.47) | <0.001 | 81 (28.7)  | 44        | 2.78 (1.84-4.19) | <0.001 |
| Perineural invasion |                  |                  |              |   |            |           |              |   |
| Negative        | 202 (86.7)                     | 23               | 1.00         |   | 234 (83.0) | 65        | 1.00         |   |
| Positive        | 31 (13.3)                      | 7                | 2.01 (0.86-4.67) | 0.107 | 48 (17.0)  | 27        | 2.39 (1.53-3.75) | <0.001 |
| Lymph node involvement |                |                  |              |   |            |           |              |   |
| Negative        | 143 (64.1)                     | 10               | 1.00         |   | 154 (56.8) | 33        | 1.00         |   |
| Positive        | 80 (35.9)                      | 17               | 3.24 (1.48-7.08) | 0.003 | 117 (43.2) | 56        | 2.76 (1.79-4.24) | <0.001 |

Abbreviations: HR, hazard ratio; CI, confidence interval; CEA, carcinoembryonic antigen; IQR, interquartile range. *Column subtotals do not sum to n of patients and n of events due to missing data. †According to the American Joint Committee on Cancer - Cancer Staging Manual (version 6.0). P ≤ 0.05 are in boldface.

Table 2. Association of MMP gene polymorphisms with distant metastasis-free survival and overall survival.

| Gene   | SNP ID    | Position | Location          | Allele | Genotype Distribution* | Best-fitting genetic models |
|--------|-----------|----------|-------------------|--------|------------------------|----------------------------|
|        |           |          |                   |        |                        | Distant metastasis-free survival | Overall survival |
|        |           |          |                   |        |                        | Model | HR (95% CI) | P | Model | HR (95% CI) | P |
| MMP2   | rs243866  | Chr16:55511537 | 5' upstream | G>A | 223/53/4 | Recessive | 6.32 (1.50-26.7) | 0.012 | Additive | 0.91 (0.78-1.45) | 0.696 |
| MMP2   | rs2285053 | Chr16:55512377 | 5' upstream | C>T | 144/121/16 | Dominant | 1.59 (0.77-3.30) | 0.213 | Additive | 0.79 (0.29-2.16) | 0.646 |
| MMP9   | rs3787268 | Chr20:44641731 | Intron 8 | G>A | 93/138/49 | Recessive | 1.55 (0.66-3.60) | 0.314 | Additive | 1.18 (0.88-1.59) | 0.260 |
| MMP9   | rs17577   | Chr20:44643111 | Exon 12 | G>A | 213/64/4 | Recessive | 2.34 (0.32-17.1) | 0.404 | Additive | 0.76 (0.47-1.22) | 0.255 |

Abbreviations: SNP, single nucleotide polymorphism; HR, hazard ratio; CI, confidence interval; MMP, matrix metalloproteinase. *The number represents major allele homozygotes, heterozygotes, and minor allele homozygotes, respectively. P ≤ 0.05 are in boldface.
been previously reported to affect receptor-positive breast cancer cell line MCF-7 cells showed reduced transcriptional activity in estrogen and functioned as an enhancer, whereas the A allele located in a potential estrogen receptor binding site [14]. In this study, we identified that colorectal cancer patients carrying AA genotype at rs243866 had a 6.32-fold higher risk of developing distant metastasis-free survival compared with those with at least one G. These results are in contrast to the previous notion that high expression levels of MMP2 in colorectal cancer is biologically plausible and has been previously reported. However, some limitations in this study should also be considered when interpreting our results. The sample size is small and we had relatively few cases with distant metastasis. In addition, our homogeneous Chinese Han population might make our findings less generalizable to other ethnic groups. Additional studies in other populations are necessary to validate our findings.

In conclusion, our findings suggest that genetic variants in MMP2 might modulate colorectal cancer metastasis. We are able to identify subgroups of pa-

Table 3. Cox proportional hazards analysis of MMP2 genetic interaction profiles and distant metastasis-free survival.

| Variables | n (%) | n of events | Univariate analysis | HR (95% CI) | P | HR (95% CI) | Multivariate analysis* | P |
|-----------|-------|------------|--------------------|-------------|---|-------------|------------------------|---|
| MMP2 gene polymorphisms |       |            |                    |             |   |             |                        |   |
| Low risk  | 85 (36.5) | 5          | 1.00               | 1.00        |   |             |                        |   |
| Medium risk | 113 (48.5) | 18         | 2.79 (1.04-7.53)  | **0.042**   |   | 3.73 (1.18-11.8) | **0.025**             |   |
| High risk | 35 (15.0)  | 7          | 3.70 (1.18-11.7)  | **0.025**   |   | 3.37 (0.86-13.2) | 0.082                 |   |
| Trend     | 187 (12.3-12.12) | 0.017    | 1.87 (1.12-3.12)  | **0.017**   |   | 1.77 (1.00-3.15) | **0.050**             |   |

Abbreviations: HR, hazard ratio; CI, confidence interval; MMP, matrix metalloproteinase. *Age, gender, CEA levels, tumor differentiation, stage, lymphovascular invasion, perineural invasion, lymph node involvement, and genetic risk classification by MMP2 polymorphisms were included in the multivariate analysis. P ≤ 0.05 are in boldface.

Discussion

The expression levels of MMP2 and MMP9 have been shown to be correlated with colorectal cancer initiation, progression, angiogenesis, metastasis, and recurrence [27-29]. Many studies have also proved that MMP SNPs have associations with cancer susceptibility including colorectal cancer [6-10], but little is known about their prognostic significance. In the present study, we found MMP2 rs243866 and a higher-order genetic interaction profile between MMP2 rs243866 and MMP2 rs2285053 were significantly associated with distant metastasis-free survival in colorectal cancer patients receiving curative surgery. Moreover, the association between the genetic interaction profile and distant metastasis-free survival persisted despite controlling for known clinical prognostic factors, including age, gender, CEA levels, tumor differentiation, stage, lymphovascular invasion, perineural invasion, and lymph node involvement.

The MMP2 rs2285053 (-735) C to T transition has been previously reported to affect MMP2 transcription due to the ablation of specificity protein (Sp) 1 transcription factor binding [15, 16]. Similarly, it has also been reported that the MMP2 rs243866 G allele located in a potential estrogen receptor binding site and functioned as an enhancer, whereas the A allele showed reduced transcriptional activity in estrogen receptor-positive breast cancer cell line MCF-7 cells [14]. In this study, we identified that colorectal cancer patients carrying AA genotype at MMP2 rs243866 had a 6.32-fold higher risk of developing distant metastasis after curative surgery compared with those with at least one G. These results are in contrast to the previous notion that high expression levels of MMP2 in colorectal cancer is biologically plausible and has been previously reported. However, some limitations in this study should also be considered when interpreting our results. The sample size is small and we had relatively few cases with distant metastasis. In addition, our homogeneous Chinese Han population might make our findings less generalizable to other ethnic groups. Additional studies in other populations are necessary to validate our findings.

In conclusion, our findings suggest that genetic variants in MMP2 might modulate colorectal cancer metastasis. We are able to identify subgroups of pa-
patients with different genetic profiles at MMP2 and predict their distant metastasis-free survival after curative surgery.

**Abbreviations**

MMP, matrix metalloproteinase; SNP, single nucleotide polymorphism; CEA, carcinoembryonic antigen; IQR, interquartile range; HR, hazard ratio; CI, confidence interval.

**Acknowledgements**

This work was supported by the National Science Council (NSC), Taiwan (grant number: grants NSC-98-2320-B-039-019-MY3 and NSC-100-2314-B-039-009-MY3), and China Medical University (grant number: CMU98-N1-21 and CMU98-C-12). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. We thank the National Center for Genome Medicine at Academia Sinica, Taiwan, for genotyping/technical support.

**Competing Interests**

The authors have declared that no competing interest exists.

**References**

1. O’Connell JB, Maggard MA, Ko CY. Colon cancer survival rates with the new American Joint Committee on Cancer sixth edition staging. J Natl Cancer Inst. 2004; 96: 1420-2.
2. August DA, Ottow RT, Sugarbaker PH. Clinical perspective of human colorectal cancer metastasis. Cancer Metastasis Rev. 1984; 3: 303-24.
3. Langers AM, Sier CF, Hawinkels LJ, et al. MMP -2 geno-phenotype is prognostic for colorectal cancer survival, whereas MMP -9 is not. Br J Cancer. 2008; 98: 1820-3.
4. van der Jagt MF, Sweep FC, Waas ET, et al. Correlation of extracellular matrix metalloproteinase inducer (EMMPRIN), with serum MMP-9 as a test for colorectal cancer in a primary care population. BMC Cancer. 2006; 6: 258.
5. Elander N, Soderkvist P, Fransen K. Matrix metalloproteinase (MMP) -1, -2, -3 and -9 promoter polymorphisms in colorectal cancer. Anticancer Res. 2006; 26: 791-5.
6. Woo M, Park K, Nam J, et al. Clinical implications of matrix metalloproteinase-1,-3,-7,-9,-12, and plasminogen activator inhibitor-1 gene polymorphisms in colorectal cancer. J Gastroenterol Hepatol. 2007; 22: 1064-70.
7. Xing LL, Wang ZN, Jiang L, et al. Matrix metalloproteinase-9-1562C>T polymorphism may increase the risk of lymphatic metastasis of colorectal cancer. World J Gastroenterol. 2007; 13: 4626-9.
8. Xu E, Lai M, Lv B, et al. A single nucleotide polymorphism in the matrix metalloproteinase-2 promoter is associated with colorectal cancer. Biochem Biophys Res Commun. 2004; 324: 999-1003.
9. Xu E, Xia X, Lu B, et al. Association of matrix metalloproteinase-2 and -9 promoter polymorphisms with colorectal cancer in Chinese. Mol Carcinog. 2007; 46: 924-9.
10. Beeghly-Fadiel A, Lu W, Long JR, et al. Matrix metalloproteinase-2 polymorphisms and breast cancer susceptibility. Cancer Epidemiol Biomarkers Prev. 2009; 18: 1770-6.
11. Beeghly-Fadiel A, Lu W, Shu XO, et al. MMP9 polymorphisms and breast cancer risk: a report from the Shanghai Breast Cancer Genetics Study. Breast Cancer Res Treat. 2011; 126: 507-13.
12. Jacobs EJ, Hsing AW, Bain EB, et al. Polymorphisms in angiogenesis-related genes and prostate cancer. Cancer Epidemiol Biomarkers Prev. 2008; 17: 972-7.
13. Harendza S, Lovett DH, Panzer U, et al. Linked common polymorphisms in the gelatinase a promoter are associated with diminished transcriptional response to estrogen and genetic fitness. J Biol Chem. 2003; 278: 20490-9.
14. Price SJ, Greaves DR, Watkins H. Identification of novel, functional genetic variants in the human matrix metalloproteinase-2 gene: role of Sp1 in allele-specific transcriptional regulation. J Biol Chem. 2001; 276: 7549-58.
15. Yu C, Zhou Y, Miao X, et al. Functional haplotypes in the promoter of matrix metalloproteinase-2 predict risk of the occurrence and metastasis of esophageal cancer. Cancer Res. 2004; 64: 7622-8.
16. Yang ZH, Li SN, Liu JX, et al. MMP-9 polymorphisms are related to serum lipids levels but not associated with colorectal cancer susceptibility in Chinese population. Mol Biol Rep. 2012; 39: 9399-404.
17. Han YJ, Kim HN, Yoon JK, et al. Haplotype analysis of the matrix metalloproteinase-9 gene associated with advanced-stage endometriosis. Fertil Steril. 2009; 91: 2324-30.
18. Bao BY, Pao JB, Huang CN, et al. Significant associations of prostate cancer susceptibility variants with survival in patients treated with androgen-deprivation therapy. Int J Cancer. 2012; 130: 876-84.
19. Bao BY, Pao JB, Huang CN, et al. Polymorphisms inside microRNAs and microRNA target sites predict clinical outcomes in prostate cancer patients receiving androgen-deprivation therapy. Clin Cancer Res. 2011; 17: 928-36.
20. Bao BY, Pao JB, Lin VC, et al. Individual and cumulative association of prostate cancer susceptibility variants with clinicopathologic characteristics of the disease. Clin Chim Acta. 2010; 411: 1232-7.
21. Huang CN, Huang SP, Pao JB, et al. Genetic polymorphisms in androgen receptor-binding sites predict survival in prostate cancer patients receiving androgen-deprivation therapy. Ann Oncol. 2012; 23: 707-13.
22. Huang CN, Huang SP, Pao JB, et al. Genetic polymorphisms in oestrogen receptor-binding sites affect clinical outcomes in patients with prostate cancer receiving androgen-deprivation therapy. J Intern Med. 2012; 271: 499-509.
23. Huang SP, Lan YH, Lu TL, et al. Clinical significance of runt-related transcription factor 1 polymorphism in prostate cancer. BJU Int. 2011; 107: 486-92.
24. Wanebo HJ, Rao B, Pinsky CM, et al. Preoperative carcinoembryonic antigen level as a prognostic indicator in colorectal cancer. N Engl J Med. 1978; 299: 448-51.
25. Zhang HP, Singer B. Recursive partitioning and applications. New York: Springer; 2010.
26. Asano T, Tada M, Cheng S, et al. Prognostic values of matrix metalloproteinase family expression in human colorectal carcinoma. J Surg Res. 2008; 146: 32-42.
27. van der Jagt MF, Wobbes T, Strobbe LJ, et al. Metalloproteinases and their regulators in colorectal cancer. J Surg Oncol. 2010; 101: 259-69.
28. Zucker S, Vacicra J. Role of matrix metalloproteinases (MMPs) in colorectal cancer. Cancer Metastasis Rev. 2004; 23: 101-17.
29. Park KS, Kim SJ, Kim KH, et al. Clinical characteristics of TIMP2, MMP2, and MMP9 gene polymorphisms in colorectal cancer. J Gastroenterol Hepatol. 2011; 26: 391-7.
30. Decock J, Thirkettle S, Wagstaff L, et al. Matrix metalloproteinases: protective roles in cancer. J Cell Mol Med. 2011; 15: 1254-65.